title: Response of the benign hypertrophied prostate to treatment with an LHRH analogue.
abstract: Twenty patients with outflow tract obstruction secondary to benign prostatic hypertrophy were treated with an LHRH analogue, buserelin, for up to 6 months. Despite maintaining castrate levels of testosterone and achieving a significant reduction in tissue levels of dihydrotestosterone, no significant improvement was seen in flow rate or residual volume.
authors: Department of Urology, Royal Postgraduate Medical School, Hammersmith Hospital, London.
authors: P F
authors: PF
authors: Keane
authors: A G
authors: AG
authors: Timoney
authors: E
authors: E
authors: Kiely
authors: G
authors: G
authors: Williams
authors: G
authors: G
authors: Stamp
mesh_terms: D002064:Buserelin / Q000627:therapeutic use*; D002369:Castration; D012739:Gonadal Steroid Hormones / Q000032:analysis; D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D001748:Urinary Bladder Neck Obstruction / Q000209:etiology; D014554:Urination / Q000187:drug effects
chemical_list: D012739:Gonadal Steroid Hormones; D002064:Buserelin